Home / Deep Research / FOXE3-Related Anterior Segment Dysgenesis

FOXE3-Related Anterior Segment Dysgenesis

FOXE3-Related Anterior Segment Dysgenesis (ASD2; OMIM 610256): Comprehensive Research Report

2026-04-04
Falcon MONDO:0019503 Model: Edison Scientific Literature 28 citations

FOXE3-Related Anterior Segment Dysgenesis (ASD2; OMIM 610256): Comprehensive Research Report

Executive summary

FOXE3-related anterior segment dysgenesis is a Mendelian developmental eye disorder caused by pathogenic variants in the lens transcription factor FOXE3 (gene MIM 601094) and classically mapped to Anterior segment dysgenesis 2 (ASD2; OMIM 610256). It shows both autosomal recessive (biallelic) and autosomal dominant inheritance, with a strong genotype–phenotype relationship: biallelic loss-of-function/forkhead-domain missense variants tend to cause severe congenital malformations (corneal opacity/sclerocornea, aphakia, microphthalmia), while dominant C-terminal extension (stop-loss/non-stop) variants more often cause cataract with variable, usually milder anterior segment anomalies. (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13, iseri2009seeingclearlythe pages 2-3)

Recent (2023–2024) literature emphasizes (i) increasing availability—but high heterogeneity—of commercial gene panels for anterior segment phenotypes, (ii) the role of WES in resolving phenotypically overlapping congenital ocular disorders, and (iii) improved evidence synthesis on management and outcomes for key overlapping clinical entities (notably Peters anomaly) that frequently appear in the FOXE3 spectrum. (wowra2024generaltreatmentand pages 1-2, procopio2023comparinggenepanels pages 1-2, zucco2024abird’seye pages 3-4)

1. Disease information

1.1 Definition / overview

Anterior segment dysgenesis (ASD) comprises developmental abnormalities of the cornea, iris, lens, and iridocorneal angle. FOXE3-related ASD is a genetically defined subset in which abnormal lens development secondarily disrupts anterior segment morphogenesis, producing a spectrum from isolated cataract to severe congenital malformations such as sclerocornea–microphthalmia–aphakia complex and/or Peters anomaly. FOXE3 expression is lens-restricted, supporting a lens-primary mechanism for many downstream anterior segment findings. (iseri2009seeingclearlythe pages 1-2, iseri2009seeingclearlythe pages 2-3)

1.2 Key identifiers

1.3 Common synonyms / alternative names

Because FOXE3 variants yield multiple overlapping clinical diagnoses, the phenotype is often reported under: * Anterior segment dysgenesis (ASD) * Peters anomaly (when central corneal opacity with irido-/lenticulo-corneal adhesions is present) (doucette2011anovelnonstop pages 1-2, wowra2024generaltreatmentand pages 1-2) * Congenital primary aphakia (when lens is absent congenitally) (iseri2009seeingclearlythe pages 2-3) * Sclerocornea–microphthalmia–aphakia complex (a severe biallelic FOXE3 phenotype) (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

1.4 Evidence source type

Most FOXE3 disease knowledge comes from aggregated disease-level resources and case series (families/case reports with sequencing) plus functional assays in cell systems, and supporting developmental biology evidence from animal models (e.g., Foxe3/dyl mouse). (semina2001mutationsinthe pages 1-2, reis2021comprehensivephenotypicand pages 1-2)

2. Etiology

2.1 Primary causal factors

Genetic (monogenic) etiology: pathogenic germline variants in FOXE3, encoding a forkhead transcription factor critical for lens development. (reis2021comprehensivephenotypicand pages 1-2, iseri2009seeingclearlythe pages 2-3)

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

No validated protective environmental factors or gene–environment interactions were identified in the retrieved texts for FOXE3-specific disease; most evidence supports a primarily genetic developmental mechanism. (reis2021comprehensivephenotypicand pages 1-2, iseri2009seeingclearlythe pages 2-3)

3. Phenotypes

3.1 Core phenotype spectrum and frequencies (human)

The best quantitative synthesis in the retrieved evidence is from Reis et al. 2021, which explicitly stratifies recessive vs dominant FOXE3 disease: * Recessive/biallelic FOXE3: severe congenital phenotypes with corneal opacity (90%), sclerocornea (47%), aphakia (83%), microphthalmia (80%); when assessed, aniridia/iris hypoplasia (89%) and optic nerve anomalies (60%) were frequent. (reis2021comprehensivephenotypicand pages 1-2) * Dominant FOXE3 (often extension alleles): usually normal eye size (96%), cataracts (99%), and variable anterior segment anomalies with overlap in some individuals (microphthalmia/aphakia/sclerocornea can occur). (reis2021comprehensivephenotypicand pages 1-2)

Figure-based visual evidence for these phenotype distributions is provided in Figure 3 (Reis 2021). (reis2021comprehensivephenotypicand media 2b34c269, reis2021comprehensivephenotypicand media cd18957d)

Additional genotype-phenotype synthesis across the literature: * Recessive cases predominate in published FOXE3 cohorts (reported 84% recessive vs 16% dominant), with severe ocular disease much more frequent in recessive than dominant cases (77% vs 5%), and severity associated with truncating vs missense allele classes. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

3.2 Phenotype characteristics (typical)

Onset: Congenital/early childhood (developmental malformation present at birth; cataract may be congenital or progress/manifest later depending on allele class). (reis2021comprehensivephenotypicand pages 1-2, iseri2009seeingclearlythe pages 2-3)

Progression: Structural anomalies are generally non-progressive, but vision-threatening sequelae (e.g., amblyopia, glaucoma, corneal graft outcomes) can evolve over time. (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 4-7)

3.3 Suggested HPO terms (examples)

(ontology suggestions; confirm exact mappings during curation) * Anterior segment dysgenesis — HP:0000649 * Peters anomaly — HP:0000570 * Corneal opacity — HP:0007957 * Sclerocornea — HP:0000678 * Microphthalmia — HP:0000568 * Aphakia — HP:0000565 * Cataract — HP:0000518 * Glaucoma — HP:0000501 * Iris hypoplasia / aniridia — HP:0000528 / HP:0000526 * Optic nerve hypoplasia/anomaly — HP:0000609

3.4 Quality of life impact

Although FOXE3-specific quality-of-life instrument data were not found in the retrieved texts, the phenotype spectrum includes high-impact outcomes (childhood visual impairment/blindness, multiple surgeries, long-term amblyopia therapy and glaucoma monitoring). For Peters anomaly (a frequent overlapping entity), half of infants/children may achieve “functional vision” after surgical treatment in some series, but severe outcomes including no light perception are also reported. (wowra2024generaltreatmentand pages 7-8, wowra2024generaltreatmentand pages 4-7)

4. Genetic / molecular information

4.1 Causal gene

4.2 Pathogenic variant classes and functional consequences

A major current understanding is that variant class correlates with inheritance mode and severity: * Biallelic recessive disease: often truncating (frameshift/nonsense) or forkhead-domain missense variants consistent with reduced FOXE3 function; functional assays show variable impacts on stability/DNA binding/nuclear localization/transcriptional activity depending on substitution/position. (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13) * Dominant disease: commonly C-terminal extension/stop-loss (“elongating/non-stop”) variants; Reis et al. report dominant-negative characteristics in functional studies of dominant alleles. (reis2021comprehensivephenotypicand pages 1-2, doucette2011anovelnonstop pages 1-2)

Concrete variant-class examples documented in the literature include missense, truncating frameshift, and stop-loss/extension variants (e.g., FOXE3 p.X320ArgextX72 and related stop-codon disruptions). (iseri2009seeingclearlythe pages 2-3)

4.3 Genotype–phenotype correlations (quantitative)

Plaisancié et al. 2018 provides cross-study quantitative synthesis: * With ≥1 truncating allele: 90% (37/41) severe ocular phenotype. * With biallelic missense alleles: 69% (42/61) severe ocular disease. * ASD more frequent with two missense alleles (31%; 19/61) than with two truncating alleles (17%; 4/23). (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No FOXE3-specific modifier-gene or epigenetic disease mechanism evidence was identified in the retrieved texts.

5. Environmental information

No validated environmental contributors are established for FOXE3-related ASD2 in the retrieved evidence; disease is principally genetic and developmental. (reis2021comprehensivephenotypicand pages 1-2)

6. Mechanism / pathophysiology

6.1 Current mechanistic model (causal chain)

Upstream: germline pathogenic variant in FOXE3, a lens transcription factor with forkhead DNA-binding domain. (iseri2009seeingclearlythe pages 2-3)

Intermediate: disrupted lens development/maintenance, leading to abnormal lens epithelium behavior and lens morphogenesis; dominant and recessive alleles differ mechanistically (dominant-negative vs loss-of-function spectrum). (reis2021comprehensivephenotypicand pages 1-2)

Downstream: secondary abnormal development of adjacent anterior segment structures (cornea, iris, iridocorneal angle), producing phenotypes such as corneal opacity/sclerocornea, adhesions characteristic of Peters anomaly, and angle abnormalities predisposing to glaucoma. (doucette2011anovelnonstop pages 1-2, wowra2024generaltreatmentand pages 1-2)

6.2 Suggested GO biological process terms (examples)

(ontology suggestions; confirm during curation) * Eye development — GO:0001654 * Lens development in camera-type eye — GO:0002088 * Anterior/posterior pattern specification (eye) — related developmental GO terms * Regulation of transcription by RNA polymerase II — GO:0006357 (FOXE3 as transcription factor)

6.3 Suggested cell types (CL) and anatomical sites (UBERON)

(ontology suggestions; confirm during curation) * Lens epithelial cell (CL term; lens anterior epithelium implicated) (iseri2009seeingclearlythe pages 1-2) * UBERON structures: lens (UBERON:0000965), cornea (UBERON:0000964), iris (UBERON:0001769), anterior chamber angle / trabecular meshwork / Schlemm canal (angle structures relevant to glaucoma risk). (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 2-4)

7. Anatomical structures affected

Primary organ: eye.

Primary structures: lens (aphakia/cataract), cornea (opacity/sclerocornea), iris (hypoplasia/aniridia, adhesions), iridocorneal angle (glaucoma risk), optic nerve (anomalies in a subset). (reis2021comprehensivephenotypicand pages 1-2)

Laterality: can be bilateral or unilateral depending on allele and phenotype; microphthalmia and Peters anomaly can be unilateral or bilateral in broader ASD cohorts. (reis2021comprehensivephenotypicand pages 2-2, wowra2024generaltreatmentand pages 2-4)

8. Temporal development

Onset: congenital (developmental malformation). (reis2021comprehensivephenotypicand pages 1-2)

Course: lifelong structural ocular phenotype; clinical course largely defined by visual axis clarity, amblyopia risk, and management of complications such as glaucoma and corneal graft failure (when present). (wowra2024generaltreatmentand pages 7-8, wowra2024generaltreatmentand pages 4-7)

9. Inheritance and population

9.1 Inheritance pattern

9.2 Epidemiology

Direct prevalence/incidence of FOXE3-ASD2 is not provided in the retrieved texts.

However, broader context: * Developmental eye anomalies collectively have been cited as an important contributor to childhood visual impairment, and anophthalmia/microphthalmia has been reported around 0.6–3.2 per 10,000 in aggregated reviews, with FOXE3 accounting for a small fraction of such cases in some series. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4)

10. Diagnostics

10.1 Clinical evaluation

Common diagnostic components across FOXE3 and related ASD phenotypes include slit-lamp exam, tonometry, gonioscopy, corneal diameter measurement, and ocular biometry/ultrasound; in severe corneal opacity, exam under anesthesia is often needed. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, doucette2011anovelnonstop pages 1-2)

10.2 Imaging and ancillary testing

For Peters anomaly (often in the FOXE3 spectrum), 2024 guidance emphasizes: * Anterior-segment OCT (AS-OCT) and ultrasound biomicroscopy (UBM) * A/B-scan ultrasound when posterior pathology is suspected * Gonioscopy and (in some cases) electrophysiology to assess posterior segment function. (wowra2024generaltreatmentand pages 2-4)

10.3 Genetic testing (real-world implementation)

Gene panels (2023 snapshot)

Commercial panel testing for ASD shows substantial variability: * Across four ASD panels surveyed, FOXE3 was included in 100% (4/4) and PAX6 in 100% (4/4), but other common ASD genes (PITX2/FOXC1/CYP1B1/PITX3) were only present on ~50% of panels; PXDN was present on 75%. (procopio2023comparinggenepanels pages 2-4) * Panel scope varies widely; in a broader non-retinal panel survey, panels ranged from “1 to 893 genes” across indications, underscoring the need for careful selection and coverage review. (procopio2023comparinggenepanels pages 4-6) * Technical sensitivity varies by variant class; some labs report poor reliability for certain structural variants (e.g., CNVs <500 bp, larger indels), and variant interpretation differs among laboratories—supporting genetic counselor involvement. (procopio2023comparinggenepanels pages 6-7)

WES-based approaches (2024 cohort evidence)

A 2024 cohort study describing long-term molecular characterization of congenital ocular dysgenesis reports: * Use of WES in phenotype-overlapping congenital ocular disease and that, after filtering benign variants, “30.8% patients bore a pathogenic or likely pathogenic aberration in genes known to cause ocular dysgenesis.” (Journal of Human Genetics; Mar 2024; https://doi.org/10.1038/s10038-024-01237-6) (zucco2024abird’seye pages 3-4)

Single-gene testing

Historically, candidate-gene sequencing and positional approaches identified FOXE3 variants in families with congenital aphakia/ASD and informed inclusion of FOXE3 in diagnostic screening. (iseri2009seeingclearlythe pages 2-3)

10.4 Differential diagnosis

Genetically heterogeneous ASD disorders include variants in PAX6, PITX2, FOXC1, CYP1B1, PXDN, and others; phenotypic overlap is substantial, supporting broad-panel or exome approaches in many patients. (alkhaldi2023homozygousvariantfoxe3 pages 1-3, procopio2023comparinggenepanels pages 1-2)

11. Outcome / prognosis

FOXE3-specific long-term prognosis depends on phenotype severity and treatability of complications (glaucoma, corneal opacity, aphakia/cataract, amblyopia).

Because many FOXE3 patients are clinically managed under broader entities (e.g., Peters anomaly), recent outcome statistics for those entities are informative: * In Peters anomaly, glaucoma is reported in 30–70% of patients; up to 60% may have systemic abnormalities/developmental delays, and PA is a common congenital indication for infant corneal transplantation. (wowra2024generaltreatmentand pages 1-2) * For penetrating keratoplasty in Peters anomaly, published outcomes vary widely (examples reported): graft survival/failure rates including 30% failure at 1 year, 70% failure at 5 years, and 77% failure at 10 years in some series; rejection is a major cause, and congenital/secondary glaucoma predicts graft failure. (wowra2024generaltreatmentand pages 7-8, wowra2024generaltreatmentand pages 4-7)

12. Treatment

There is no FOXE3 gene-specific therapy in clinical use; management is phenotype-driven and typically multidisciplinary.

12.1 Management of key ocular components (current practice)

Corneal opacity / Peters anomaly-type disease * Penetrating keratoplasty (PK) is first-line when corneal opacity prevents visual development; alternatives include optical sector iridectomy, pupil dilation, corneal rotation, and keratoprosthesis in selected cases. (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 8-10) * Postoperative priorities: maintain clear visual axis and prevent amblyopia; EUAs used to monitor grafts and IOP; immunosuppression regimens may include topical corticosteroids/cyclosporine A and sometimes systemic agents. (wowra2024generaltreatmentand pages 2-4, wowra2024generaltreatmentand pages 4-7)

Glaucoma / elevated IOP * Medical therapy and surgical options (e.g., cyclophotocoagulation) are used depending on anatomy/severity; an Oman case report of FOXE3-ASD2 documented treatment with anti-glaucoma medications and CPC. (alkhaldi2023homozygousvariantfoxe3 pages 1-3)

Aphakia / cataract * Optical correction (contact lenses/spectacles) and amblyopia therapy are key; in Peters anomaly care pathways, cataract removal and secondary IOL implantation are often deferred until ~2–3 years, with contact lenses for temporary aphakia. (wowra2024generaltreatmentand pages 4-7)

12.2 Suggested MAXO terms (examples)

(ontology suggestions; confirm during curation) * Corneal transplantation / penetrating keratoplasty * Antiglaucoma pharmacotherapy * Cyclophotocoagulation * Lensectomy / cataract extraction * Amblyopia therapy (occlusion therapy, atropine penalization) * Contact lens fitting for aphakia

13. Prevention

Primary prevention is not currently available for a monogenic congenital malformation; however: * Genetic counseling and cascade testing are central. * Reproductive options may include prenatal or preimplantation genetic testing once the familial FOXE3 variant(s) are known; panel-testing reviews explicitly note that prenatal/PGT discussion is outside scope but clinically relevant. (procopio2023comparinggenepanels pages 6-7)

14. Other species / natural disease

The retrieved human-focused evidence did not provide curated naturally occurring FOXE3-related ASD in non-human species; however, vertebrate developmental biology evidence supports conserved Foxe3 function in lens/anterior segment development (see model organisms below). (semina2001mutationsinthe pages 1-2)

15. Model organisms

The retrieved evidence base includes strong support from mouse developmental genetics: * The classic dysgenetic lens (dyl) mouse mutant has Foxe3 mutations and displays small eyes, corneal opacities, iris adhesions, persistent lens–cornea attachment, and cataracts, aligning with the concept that lens-primary defects drive secondary anterior segment malformations. (semina2001mutationsinthe pages 1-2)

Additional model-organism evidence (e.g., zebrafish foxe3 deficiency) was retrieved in searches but not fully incorporated into the evidence excerpts above; it should be added during extended curation if model details are required.

Key abstract-supported quotes (for knowledge base evidence items)

Embedded summary artifact

The following table consolidates inheritance patterns, variant classes, phenotype patterns, and key quantitative frequencies.

Table (click to expand)
Inheritance mode Typical phenotype pattern Variant classes / inferred mechanism Key quantitative phenotype data Key citations
Autosomal recessive / biallelic FOXE3-related disease Usually more severe congenital ocular malformations: dense corneal opacity, sclerocornea, primary aphakia, microphthalmia; frequent iris hypoplasia/aniridia and optic nerve anomalies; may include Peters-like anterior segment dysgenesis, cataract, and occasional extraocular findings Typically truncating variants (nonsense, frameshift) throughout the single-exon gene and missense variants in the forkhead DNA-binding domain; overall most consistent with loss of function, though missense alleles show variable functional effects on protein stability, DNA binding, nuclear localization, and transcriptional activity Reis 2021: corneal opacity 90%, sclerocornea 47%, aphakia 83%, microphthalmia 80%, aniridia/iris hypoplasia 89% (when assessed), optic nerve anomalies 60% (when assessed). Plaisancié 2018: recessive cases 84% of reported FOXE3 families; severe ocular phenotype in 77% of recessive cases; among patients with ≥1 truncating allele, 90% (37/41) had severe ocular disease; among biallelic missense cases, 69% (42/61) had severe ocular disease; ASD reported in 31% (19/61) of biallelic missense vs 17% (4/23) with two truncating variants (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13) (reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)
Autosomal dominant FOXE3-related disease Typically milder and more variable anterior segment disease with congenital/early-onset cataract, Peters anomaly, iris abnormalities, microcornea, corneal scleralization, and occasional coloboma; most individuals have normal eye size, but overlap with recessive features can occur Most often C-terminal extension / non-stop / elongating variants affecting or near the stop codon; dominant alleles show severe impairment in multiple functional assays and dominant-negative behavior in Reis 2021, while earlier genotype reviews also discuss possible gain-of-function effects for elongating alleles Reis 2021: normal eye size 96%, cataract 99% in dominant pedigrees, with variable anterior segment anomalies. Plaisancié 2018: dominant cases 16% of reported FOXE3 families; severe ocular phenotype in 5% of dominant cases. Newfoundland pedigree: 11 affected among 31 examined relatives in a 4-generation family with a non-stop variant and variable ASD including Peters anomaly (reis2021comprehensivephenotypicand pages 1-2, doucette2011anovelnonstop pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13) (reis2021comprehensivephenotypicand pages 1-2, doucette2011anovelnonstop pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)
Genotype-phenotype overlap across AD and AR disease Considerable overlap exists: cataract, anterior segment dysgenesis, Peters anomaly, aphakia, sclerocornea, and microphthalmia can occur in either inheritance class, although severity trends differ Recessive missense alleles can be milder than recessive truncating alleles; dominant extension alleles usually milder but can occasionally produce features more typical of recessive disease Reis 2021 identified overlap between dominant and recessive disease and noted that some recessive cases had isolated cataract, while some dominant individuals had microphthalmia, aphakia, or sclerocornea. Plaisancié 2018 concluded that mutation type, inheritance mode, and severity are correlated but not absolute (plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4, reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13) (plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4, reis2021comprehensivephenotypicand pages 1-2, plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13)

Table: This table summarizes the main genotype-phenotype patterns in FOXE3-related anterior segment dysgenesis, contrasting autosomal recessive/biallelic and autosomal dominant disease. It highlights the typical clinical presentations, variant classes and mechanisms, and the most useful quantitative phenotype frequencies from key studies.

Limitations and curation notes

  • MONDO/Orphanet/ICD/MeSH identifiers were not retrievable from the full texts accessed here and should be completed by direct database lookup during knowledge base normalization. (iseri2009seeingclearlythe pages 2-3)
  • Many treatment/outcome statistics come from Peters anomaly management literature (2024) rather than FOXE3-genotype-stratified cohorts; however, these are clinically relevant because Peters anomaly is a common manifestation within the FOXE3 spectrum. (wowra2024generaltreatmentand pages 1-2, wowra2024generaltreatmentand pages 7-8)
  • Variant-level details (HGVS for all known FOXE3 alleles, allele frequencies in gnomAD, ClinVar assertions) require direct ClinVar/gnomAD extraction; Reis et al. note FOXE3 alleles are rare/absent in gnomAD but full frequencies were not present in the excerpted evidence. (reis2021comprehensivephenotypicand pages 1-2)

References

  1. (reis2021comprehensivephenotypicand pages 1-2): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.

  2. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 8-13): Julie Plaisancié, N. Ragge, H. Dollfus, J. Kaplan, D. Lehalle, C. Francannet, G. Morin, H. Colineaux, P. Calvas, and N. Chassaing. Foxe3 mutations: genotype‐phenotype correlations. Clinical Genetics, 93:837-845, Apr 2018. URL: https://doi.org/10.1111/cge.13177, doi:10.1111/cge.13177. This article has 42 citations and is from a peer-reviewed journal.

  3. (iseri2009seeingclearlythe pages 2-3): Sibel Ugur Iseri, Robert J. Osborne, Martin Farrall, Alexander William Wyatt, Ghazala Mirza, Gudrun Nürnberg, Christian Kluck, Helen Herbert, Angela Martin, Muhammad Sajid Hussain, J. Richard O. Collin, Mark Lathrop, Peter Nürnberg, Jiannis Ragoussis, and Nicola K. Ragge. Seeing clearly: the dominant and recessive nature of foxe3 in eye developmental anomalies. Human Mutation, 30:1378-1386, Oct 2009. URL: https://doi.org/10.1002/humu.21079, doi:10.1002/humu.21079. This article has 109 citations and is from a domain leading peer-reviewed journal.

  4. (wowra2024generaltreatmentand pages 1-2): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.

  5. (procopio2023comparinggenepanels pages 1-2): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.

  6. (zucco2024abird’seye pages 3-4): Jessica Zucco, Federica Baldan, Lorenzo Allegri, Elisa Bregant, Nadia Passon, Alessandra Franzoni, Angela Valentina D’Elia, Flavio Faletra, Giuseppe Damante, and Catia Mio. A bird’s eye view on the use of whole exome sequencing in rare congenital ophthalmic diseases. Journal of Human Genetics, 69:271-282, Mar 2024. URL: https://doi.org/10.1038/s10038-024-01237-6, doi:10.1038/s10038-024-01237-6. This article has 9 citations and is from a peer-reviewed journal.

  7. (iseri2009seeingclearlythe pages 1-2): Sibel Ugur Iseri, Robert J. Osborne, Martin Farrall, Alexander William Wyatt, Ghazala Mirza, Gudrun Nürnberg, Christian Kluck, Helen Herbert, Angela Martin, Muhammad Sajid Hussain, J. Richard O. Collin, Mark Lathrop, Peter Nürnberg, Jiannis Ragoussis, and Nicola K. Ragge. Seeing clearly: the dominant and recessive nature of foxe3 in eye developmental anomalies. Human Mutation, 30:1378-1386, Oct 2009. URL: https://doi.org/10.1002/humu.21079, doi:10.1002/humu.21079. This article has 109 citations and is from a domain leading peer-reviewed journal.

  8. (reis2021comprehensivephenotypicand pages 2-2): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.

  9. (alkhaldi2023homozygousvariantfoxe3 pages 1-3): Zuha Alkhaldi, Moosa Allawati, and Nadia Alhashmi. Homozygous variant foxe3 causes autosomal recessive anterior segment dysgenesis type 2: a case report. Journal of Biochemical and Clinical Genetics, pages 75-79, Jan 2023. URL: https://doi.org/10.24911/jbcgenetics/183-1670866871, doi:10.24911/jbcgenetics/183-1670866871. This article has 0 citations.

  10. (reis2021comprehensivephenotypicand pages 14-14): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.

  11. (doucette2011anovelnonstop pages 1-2): Lance Doucette, Jane Green, Bridget Fernandez, Gordon J Johnson, Patrick Parfrey, and Terry-Lynn Young. A novel, non-stop mutation in foxe3 causes an autosomal dominant form of variable anterior segment dysgenesis including peters anomaly. European Journal of Human Genetics, 19:293-299, Mar 2011. URL: https://doi.org/10.1038/ejhg.2010.210, doi:10.1038/ejhg.2010.210. This article has 55 citations and is from a domain leading peer-reviewed journal.

  12. (semina2001mutationsinthe pages 1-2): E. Semina, Isaac Brownell, H. Mintz‐Hittner, Jeffrey C. Murray, and M. Jamrich. Mutations in the human forkhead transcription factor foxe3 associated with anterior segment ocular dysgenesis and cataracts. Human molecular genetics, 10 3:231-6, Feb 2001. URL: https://doi.org/10.1093/hmg/10.3.231, doi:10.1093/hmg/10.3.231. This article has 239 citations and is from a domain leading peer-reviewed journal.

  13. (reis2021comprehensivephenotypicand media 2b34c269): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.

  14. (reis2021comprehensivephenotypicand media cd18957d): Linda M Reis, Elena A Sorokina, Lubica Dudakova, Jana Moravikova, Pavlina Skalicka, Frantisek Malinka, Sarah E Seese, Samuel Thompson, Tanya Bardakjian, Jenina Capasso, William Allen, Tom Glaser, Alex V Levin, Adele Schneider, Ayesha Khan, Petra Liskova, and Elena V Semina. Comprehensive phenotypic and functional analysis of dominant and recessive foxe3 alleles in ocular developmental disorders. Human Molecular Genetics, 30:1591-1606, May 2021. URL: https://doi.org/10.1093/hmg/ddab142, doi:10.1093/hmg/ddab142. This article has 22 citations and is from a domain leading peer-reviewed journal.

  15. (wowra2024generaltreatmentand pages 4-7): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.

  16. (wowra2024generaltreatmentand pages 7-8): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.

  17. (wowra2024generaltreatmentand pages 2-4): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.

  18. (plaisancie2018foxe3mutationsgenotype‐phenotype pages 1-4): Julie Plaisancié, N. Ragge, H. Dollfus, J. Kaplan, D. Lehalle, C. Francannet, G. Morin, H. Colineaux, P. Calvas, and N. Chassaing. Foxe3 mutations: genotype‐phenotype correlations. Clinical Genetics, 93:837-845, Apr 2018. URL: https://doi.org/10.1111/cge.13177, doi:10.1111/cge.13177. This article has 42 citations and is from a peer-reviewed journal.

  19. (procopio2023comparinggenepanels pages 2-4): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.

  20. (procopio2023comparinggenepanels pages 4-6): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.

  21. (procopio2023comparinggenepanels pages 6-7): Rebecca Procopio, Jose S. Pulido, Kammi B. Gunton, Zeba A. Syed, Daniel Lee, Mark L. Moster, Robert Sergott, Julie A. Neidich, and Margaret M. Reynolds. Comparing gene panels for non-retinal indications: a systematic review. Genes, 14:738, Mar 2023. URL: https://doi.org/10.3390/genes14030738, doi:10.3390/genes14030738. This article has 0 citations.

  22. (wowra2024generaltreatmentand pages 8-10): Bogumil Wowra, Dariusz Dobrowolski, Mohit Parekh, and Edward Wylęgała. General treatment and ophthalmic management of peters’ anomaly. Journal of Clinical Medicine, 13:532, Jan 2024. URL: https://doi.org/10.3390/jcm13020532, doi:10.3390/jcm13020532. This article has 6 citations.